Amendment: SEC Form SC 13G/A filed by Solventum Corporation
$SOLV
Medical/Dental Instruments
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/6/2025 | Sector Weight | KeyBanc Capital Markets | |
| 5/19/2025 | $87.00 | Neutral → Overweight | Piper Sandler |
| 12/4/2024 | $70.00 | Neutral | Mizuho |
| 10/8/2024 | $82.00 | Buy | Stifel |
| 10/7/2024 | $71.00 | Neutral | Piper Sandler |
| 9/26/2024 | Peer Perform | Wolfe Research | |
| 9/5/2024 | Neutral | BTIG Research | |
| 6/24/2024 | Hold | Argus |
Recognized among the top 25 percent of companies in healthcare and research, and top 25 percent of companies in the Midwest in just 14 months as a new company Award highlights success in phase one of Solventum's three-phased Transformation Plan ST. PAUL, Minn., June 18, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV), a global leader in innovative medical technology and solutions, today announced U.S. News & World Report has named the company among its 2025-2026 list of Best Companies to Work For, earning top honors in three categories: Best Companies OverallHealth Care and Resear
ST. PAUL, Minn., June 3, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today its executives will participate in a fireside chat at the Goldman Sachs 46th Annual Global Health Care Conference on Tuesday, June 10, 2025, beginning at approximately 4:00 p.m. EDT in Miami, FL. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com. About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' tou
Reported sales increased 2.6%; organic sales increased 4.3%Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5%ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales increased 2.6% to $2.1 billion; up 4.3% on an organic basisGAAP diluted earnings per share of $0.78; adjusted diluted earnings per share of $1.34Operating cash flow of $29 million; free cash flow of $(80) million"Our first quarter fiscal year 2025 results reflect soli
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
KeyBanc Capital Markets initiated coverage of Solventum Corporation with a rating of Sector Weight
Piper Sandler upgraded Solventum Corporation from Neutral to Overweight and set a new price target of $87.00
Mizuho initiated coverage of Solventum Corporation with a rating of Neutral and set a new price target of $70.00